Suneel D. Kamath, MD

Suneel K. Kamath, MD, et al investigated exceptional responders and the correlation of nonsynonymous mutations for patients with advanced pancreatic cancer.

A panel of expert oncologists offer closing thoughts on the future treatment landscape and unmet needs in colorectal cancer.

An expert panel discusses clinical trials focused on circulating tumor DNA in guiding treatment selection in colorectal cancer.

An overview of the SUNLIGHT and FRESCO-2 studies in the refractory colorectal cancer space.

A panel of experts discuss the role of ctDNA and their practices for retesting HER2 expression to guide treatment for colorectal cancer.

A comprehensive overview of trastuzumab deruxtecan (T-DXd) as a treatment for patients with HER2+ metastatic colorectal cancer.

Arshiya Mariam, BS, and colleagues report the findings of a large meta-analysis assessing the ability of various biomarkers to predict responses to immune checkpoint inhibition.

Experts on colorectal cancer present the case of a 40-year-old woman with CRC, who receives later-line treatment with trastuzumab deruxtecan, and share their initial thoughts.

Insights on the role of circulating tumor DNA in treatment selection for patients with metastatic colorectal cancer.

Arvind Dasari, MD, MS, reviews the PARADIGM study on EGFR-targeting therapy in metastatic colorectal cancer.

Expert oncologists present the case of a 47-year-old woman with colorectal cancer and early disease progression, and discuss treatment options with the ongoing MOUNTAINEER-03 study.

Experts on HER2+ metastatic colorectal cancer review the MOUNTAINEER study on tucatinib plus trastuzumab.

An overview of the treatment landscape for HER2+ metastatic colorectal cancer and recent updates to the NCCN Guidelines.

Expert oncologists discuss the landscape surrounding HER2+ metastatic CRC, including recommendations for biomarker testing and an overview of scoring criteria.

A panel of expert oncologists present the case of a 46-year-old woman with HER2+ metastatic colorectal cancer, who is treated with tucatinib in the second-line setting.

Minh-Tri Nguyen, MD, and colleagues investigate the association between time to treatment, socioeconomic status, and clinical outcomes among rural and urban patients with breast cancer.

Suneel D. Kamath, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on how financial conflicts of interest correlate with success of early-career academic oncologist.

Conflicts of interest for junior faculty members were evaluated at top cancer centers by Suneel D. Kamath, MD, et al. to determine how financial conflicts of interest correlated with measures of academic career productivity.